A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity

Clinical Cancer Research

Volumn 18, Issue 24, 2012, Pages 6679-6689

  Tysome, James R ^a,d   Li, Xiaozhu ^b   Wang, Shengdian ^b,d   Wang, Pengju ^a   Gao, Dongling ^a   Du, Pan ^a   Chen, Dong ^c   Gangeswaran, Rathi ^d   Chard, Louisa S ^d   Yuan, Ming ^d   Alusi, Ghassan ^d   Lemoine, Nicholas R ^a,d   Wang, Yaohe ^a,d  

^a ZHENGZHOU UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HAMSTER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CARCINOMA; PRIORITY JOURNAL; T CELL DEPLETION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; APOPTOSIS; CELLS, CULTURED; CRICETINAE; FEMALE; HUMANS; IMMUNOCOMPETENCE; KIDNEY NEOPLASMS; MESOCRICETUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871242979     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0979     Document Type: Article

References (45)

1. Wong HH, Lemoine NR, Wang Y. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2010;2:78-106.
2. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008;8:1581-8.
3. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76. (Pubitemid 41766784)
4. Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 2008;68:4882-92.
5. Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L. The highly attenuated vaccinia virus strain modi fied virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol 2006;146:344-53. (Pubitemid 44581351)
6. Kaufman HL. The role of poxviruses in tumor immunotherapy. Surgery 2003;134:731-7. (Pubitemid 37523955)
7. Yang Y, Li X, Wang Y, Wang S. CD8+ T cell response mediates the therapeutic effects of oncolytic adenovirus in an mmunocompetent mouse model. Chin Sci Bull 2012;57:48-53.
8. Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci U S A 2001;98:11491-6. (Pubitemid 32928756)
9. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 2008;14:819-21.
10. Hallden G, Hill R, Wang Y, Anand A, Liu TC, Lemoine NR, et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003;8: 412-24. (Pubitemid 37161463)
11. Ganly I, Mautner V, Balmain A. Productive replication of human adenoviruses in mouse epidermal cells. J Virol 2000;74:2895-9. (Pubitemid 30117602)
12. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist 2002;7:46-59. (Pubitemid 34151107)
13. Silobrcic V, Zietman AL, Ramsay JR, Suit HD, Sedlacek RS. Residual immunity of athymic NCr/Sed nude mice and the xenotransplantation of human tumors. Int J Cancer 1990;45:325-33. (Pubitemid 20061389)
14. Thomas MA, Spencer JF, Wold WS. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 2007;130:169-83.
15. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006;66:1270-6. (Pubitemid 43259903)
16. Toth K, Spencer JF, Wold WS. Immunocompetent, semi-permissive cotton rat tumor model for the evaluation of oncolytic adenoviruses. Methods Mol Med 2007;130:157-68.
17. Liu TC, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N, et al. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 2004;9:786-803. (Pubitemid 38878125)
18. Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL, et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005;16:139-46. (Pubitemid 40250340)
19. Hung CF, Tsai YC, He L, Coukos G, Fodor I, Qin L, et al. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther 2007;14:20-9. (Pubitemid 44942862)
20. Gnant MF, Puhlmann M, Alexander HR Jr, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999;59:3396-403. (Pubitemid 29334499)
21. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000;7:66-73. (Pubitemid 30080989)
22. Qin H, Valentino J, Manna S, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, et al. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol Ther 2001;4:551-8. (Pubitemid 34026870)
23. Hanabuchi S, Ohashi T, Koya Y, Kato H, Hasegawa A, Takemura F, et al. Regression of human T-cell leukemia virus type I (HTLV-I)- associated lymphomas in a rat model: peptide-induced T-cell immunity. J Natl Cancer Inst 2001;93:1775-83. (Pubitemid 33150449)
24. Derby ML, Sena-Esteves M, Breakefield XO, Corey DP. Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. Hear Res 1999;134:1-8. (Pubitemid 29354511)
25. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997;238:198-211. (Pubitemid 28218138)
26. Nelles MJ, Duncan WR, Streilein JW. Immune response to acute virus infection in the Syrian hamster. II. Studies on the identity of virus-induced cytotoxic effector cells. J Immunol 1981;126:214-8. (Pubitemid 11218905)
27. Melby PC, Chandrasekar B, Zhao W, Coe JE. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 2001;166:1912-20. (Pubitemid 32114678)
28. van Den Broek M, Bachmann MF, Kohler G, Barner M, Escher R, Zinkernagel R, et al. IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2. J Immunol 2000;164:371-8. (Pubitemid 30013011)
29. Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003;21:1328-35. (Pubitemid 37356618)
30. Dhar D, Spencer JF, Toth K, Wold WS. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virology 2009;83:2130-9.
31. Tysome JR, Briat A, Alusi G, Cao F, Gao D, Yu J, et al. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther 2009;16:1223-33.
32. Tysome JR, Wang P, Alusi G, Briat A, Gangeswaran R, Wang J, et al. Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer. Hum Gene Ther 2011;22:1101-8.
33. Deng H, Tang N, Stief AE, Mehta N, Baig E, Head R, et al. Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus. Leukemia. 2008;22:2261-4.
34. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-7. (Pubitemid 34013887)
35. Wong HH, Jiang G, Gangeswaran R, Wang P, Wang J, Yuan M, et al. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. Mol Ther 2012;20:306-16.
36. Thorne SH. Immunotherapeutic potential of oncolytic vaccinia virus. Immunol Res 2011;50:286-93.
37. Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010;18:888-95.
38. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402. (Pubitemid 28212753)
39. Tufariello JM, Cho S, Horwitz MS. Adenovirus E3 14.7-kilodalton protein, an antagonist of tumor necrosis factor cytolysis, increases the virulence of vaccinia virus in severe combined immunodeficient mice. Proc Natl Acad Sci U S A 1994;91:10987-91. (Pubitemid 24349610)
40. Tufariello J, Cho S, Horwitz MS. The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model. J Virol 1994;68:453-62.
41. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357-68. (Pubitemid 351430366)
42. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007;117:3350-8. (Pubitemid 350096991)
43. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477:99-102.
44. Liu TC, Galanis E,Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17. (Pubitemid 46189539)
45. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42.